Talphera Inc (TLPH)

$1.03

-0.01

(-0.96%)

Market is closed - opens 7 PM, 28 May 2024

Insights on Talphera Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 117.0K → 281.0K (in $), with an average increase of 58.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -4.51M → -3.95M (in $), with an average increase of 14.2% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 52.8% return, outperforming this stock by 60.0%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 43.5% return, outperforming this stock by 139.9%

Performance

  • $1.02
    $1.04
    $1.03
    downward going graph

    0.97%

    Downside

    Day's Volatility :1.92%

    Upside

    0.96%

    downward going graph
  • $0.43
    $1.61
    $1.03
    downward going graph

    58.74%

    Downside

    52 Weeks Volatility :73.6%

    Upside

    36.02%

    downward going graph

Returns

PeriodTalphera IncIndex (Russel 2000)
3 Months
-24.82%
0.0%
6 Months
39.19%
0.0%
1 Year
4.8%
0.0%
3 Years
-96.42%
-22.2%

Highlights

Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
0.0%
Return On Equity TTM
0.0%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
0.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0

Analyst Recommendation

Analyst Forecast

What analysts predicted

Upside of 349.51%

Current $1.03
Target $4.63

Technicals Summary

Sell

Neutral

Buy

Talphera Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Talphera Inc
Talphera Inc
4.04%
39.19%
4.8%
-96.42%
-98.03%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
0.37%
23.34%
54.7%
43.49%
75.5%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-1.06%
-2.78%
3.84%
13.09%
13.09%
Zoetis Inc.
Zoetis Inc.
6.49%
-4.88%
5.67%
-2.63%
66.7%
Viatris Inc.
Viatris Inc.
-11.63%
11.46%
13.4%
-31.24%
-36.29%
Catalent, Inc.
Catalent, Inc.
-2.63%
40.17%
50.52%
-47.84%
21.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Talphera Inc
Talphera Inc
NA
NA
NA
0.0
0.0
0.0
NA
NA
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
38.18
38.18
0.44
4.06
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.2
28.2
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
32.87
32.87
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.05
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.25
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Talphera Inc
Talphera Inc
NA
$23.6M
-98.03%
NA
0.0%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
75.5%
38.18
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.6B
13.09%
28.2
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$78.5B
66.7%
32.87
27.38%
Viatris Inc.
Viatris Inc.
Hold
$12.5B
-36.29%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$9.9B
21.93%
211.02
-28.44%

Company Information

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Organization
Talphera Inc
Employees
15
CEO
Mr. Vincent J. Angotti
Industry
Miscellaneous

FAQs